The key elements of the pathway considered during the validation were LRRK2 G2019S mutation, Wnt, DDIT3, GSK3B, TFEB, PHLPP, RPS6KB1, and 4EBP2, which are involved in the development and progression of PD (Bravo-San Pedro et al., 2013; Poret and Guziolowski, 2018; Zhu et al., 2019; McCabe et al., 2020). Here, LRRK2 is linked to Parkinson disease.